Literature DB >> 16258785

[Cost-effectiveness of prevention of coronary disease in Germany].

K W Lauterbach1, A Gerber, G Klever-Deichert, B Stollenwerk.   

Abstract

It is generally accepted that the incidence of coronary heart disease can effectively be reduced by strengthening prevention. At the same time, it is still unclear how large the effects of life-style oriented preventive measurements such as diet and exercising are in everyday life. Furthermore, there is an ongoing debate on what measurements are effective. Thus, against the background of dwindling financial resources in health care the input of health economic evaluation is explicated. General issues of health economic evaluation are presented. After that, an overview on the current findings of cost-effectiveness in primary prevention of coronary heart disease is given. Risk factors are separately discussed. It is demonstrated that preventive measurements dealing especially with hypertension and hypercholesterolemia can be cost-effective.

Entities:  

Mesh:

Year:  2005        PMID: 16258785     DOI: 10.1007/s00392-005-1314-y

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  18 in total

1.  [Real and assumed potential savings in antihypertensive treatment. Right out of the magician's hat].

Authors:  M Anlauf; H-W Hense
Journal:  Dtsch Med Wochenschr       Date:  2003-07-11       Impact factor: 0.628

2.  [Primary prevention and health promotion--health science fundamentals for health policy].

Authors:  R Rosenbrock
Journal:  Gesundheitswesen       Date:  2004-03

Review 3.  A concise review of the cost-effectiveness of coronary heart disease prevention.

Authors:  A I Brown; A M Garber
Journal:  Med Clin North Am       Date:  2000-01       Impact factor: 5.456

4.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

5.  Modelling the effects of increased physical activity on coronary heart disease in England and Wales.

Authors:  B Naidoo; M Thorogood; K McPherson; L J Gunning-Schepers
Journal:  J Epidemiol Community Health       Date:  1997-04       Impact factor: 3.710

Review 6.  Cost-benefit of treating hypertension.

Authors:  B G Jönsson
Journal:  J Hypertens Suppl       Date:  1994-12

Review 7.  27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 6. Cost effectiveness of assessment and management of risk factors.

Authors:  L Goldman; A M Garber; S A Grover; M A Hlatky
Journal:  J Am Coll Cardiol       Date:  1996-04       Impact factor: 24.094

8.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

Authors:  Lindon M H Wing; Christopher M Reid; Philip Ryan; Lawrence J Beilin; Mark A Brown; Garry L R Jennings; Colin I Johnston; John J McNeil; Graham J Macdonald; John E Marley; Trefor O Morgan; Malcolm J West
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

9.  Major risk factors as antecedents of fatal and nonfatal coronary heart disease events.

Authors:  Philip Greenland; Maria Deloria Knoll; Jeremiah Stamler; James D Neaton; Alan R Dyer; Daniel B Garside; Peter W Wilson
Journal:  JAMA       Date:  2003-08-20       Impact factor: 56.272

10.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

View more
  2 in total

1.  Cardiovascular prevention in clinical practice (ESC and German guidelines 2007).

Authors:  Helmut Gohlke; Christian Albus; Detlef Bernd Gysan; Harry W Hahmann; Peter Mathes
Journal:  Herz       Date:  2009-02       Impact factor: 1.443

2.  [Health in older age: cost of illness and cost-effectiveness of prevention].

Authors:  I Brandes; U Walter
Journal:  Z Gerontol Geriatr       Date:  2007-08       Impact factor: 1.281

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.